Novel Variant Findings and Challenges Associated With the Clinical Integration of Genomic Testing

Authors:

Abstract
An estimated 10% to 25% of neonates in neonatal intensive care units have an undiagnosed genetic disorder.1-3 Because of the nonspecific presentation of many genetic disorders, affected neonates (1) have a 40% longer hospitalization,4 (2) may not receive a diagnosis, (3) may be misdiagnosed, and (4) often have a prolonged diagnostic odyssey.5 The Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT) trials demonstrated the important role that rapid sequencing can have in providing a timely genetic diagnosis to improve neonatal outcome.3,6-9 However, these platforms remain expensive and involve complex ethical dilemmas.10 A targeted sequencing approach aimed at disorders presenting in the first year of life could limit incidental findings and reduce costs. However, the diagnostic capability of such a platform is unproven and must be compared with more standardized whole-genomic sequencing (WGS) technology prior to routine use.

This publication has 33 references indexed in Scilit: